BODIPY derivative with antibacterial activity and application thereof

Abstract

The invention discloses a BODIPY derivative and application thereof, the BODIPY derivative is a compound with a structure shown as a general formula (I), in the formula (I), R1, R2, R3, R4, R5 and R6 are independently selected from hydrogen atoms, C1-C6 alkyl groups, C2-C6 alkenyl groups, C3-C8 carbocyclic groups, C1-C6 alkoxy groups, amino groups or substituted amino groups, halogen, pseudo-halogen groups, C1-C6 acyloxy groups, carbonyl groups, carboxyl groups, ester groups, substituted or unsubstituted phenyl groups and nitryl groups; r7 is a hydrogen atom or a carboxyl group; R8 and R9 are hydroxyl groups or hydrogen atoms; ar is an aromatic group; and m and n are integers from 0 to 6. The BODIPY derivative not only can endow a coating with good base material adhesion performance, but also can realize an efficient photodynamic antibacterial effect, and meanwhile, effectively overcomes the defects in the prior art.

Description

Technical Field

[0001] This invention belongs to the field of antibacterial compounds, specifically relating to a novel dopamine-modified BODIPY, which is a new compound that can be used as an antibacterial coating. Background Technology

[0002] In many fields, the antibacterial properties of material surfaces are crucial: bacterial growth on the surface of medical devices can easily lead to patient infections; microbial contamination on the surface of food processing equipment directly affects food quality and safety. However, current mainstream antibacterial coatings still have significant shortcomings and cannot meet the needs of practical applications: some coatings rely on antibiotics or heavy metal ions, which can inhibit bacteria in the short term but easily induce bacterial resistance and cause environmental pollution; other coatings have problems such as poor substrate adhesion and easy volatilization of components, resulting in short service life and inability to maintain antibacterial effects for a long time in complex environments.

[0003] In response to this situation, two promising technological directions have emerged in existing research, but both have limitations: On the one hand, mussel-inspired materials, due to the presence of components such as dopamine, have excellent substrate adhesion capabilities and can firmly adhere to various surfaces, but their antibacterial function is weak and they are unable to cope with complex microbial environments; on the other hand, photodynamic antibacterial technology uses light of specific wavelengths to induce photodynamic substances to generate active oxygen to kill bacteria, which has advantages such as high efficiency and low resistance to drug development. However, traditional photodynamic coatings generally lack good substrate adhesion performance, limiting their application range. In addition, although there are reports on acid-triggered BODIPY-based photodynamic antibacterial nanoplatforms (IBPAAs), their preparation process is cumbersome and costly, and they also have problems such as a narrow pH range and a colloidal state that cannot be fixed to the material surface, which further limits their practical application scenarios (Liang, X., Xia, L., Zhu, Y., Zhang, C., Gong, F., & Zhang, W. (2022). An acid-triggered BODIPY-based photosensitizer for enhanced photodynamic antibacterialefficacy. Biomaterials Science, 10, 4235.).

[0004] Therefore, developing a novel material that combines excellent adhesion properties with efficient photodynamic antibacterial effects has become a key issue that urgently needs to be addressed in this field. Summary of the Invention

[0005] This invention provides a dopamine-modified BODIPY derivative, which, compared with existing compounds, has both adsorption and photodynamic antibacterial effects, and can be used as a more promising antibacterial coating.

[0006] One of the objectives of this invention relates to a BODIPY derivative, the structure of which is shown in general formula (Ⅰ):

[0007]

[0008] In formula (Ⅰ), R1, R2, R3, R4, R5 and R6 can be independently selected from hydrogen atoms, alkyl, alkenyl-, carbocyclic, alkoxy, amino or substituted amino, halogen, pseudohalogen group, acyloxy, carbonyl, carboxyl, ester group, substituted or unsubstituted phenyl, nitro group;

[0009] R7 is a hydrogen atom or a carboxyl group, and R8 and R9 are hydroxyl groups or hydrogen atoms;

[0010] Ar is an aromatic group;

[0011] m and n are integers from 0 to 5.

[0012] The above-mentioned alkyl groups include, but are not limited to, substituted or unsubstituted C4 groups. 1-6 Alkyl and alkenyl groups, including substituted or unsubstituted C4 groups. 2-6 alkenyl;

[0013] Carbocyclic groups include, but are not limited to, substituted or unsubstituted C groups. 3-6 Carbon cyclic group.

[0014] The structural formula of the above alkoxy group is -OR w Among them, R w Including but not limited to hydrogen atoms, substituted or unsubstituted C atoms 1-6 Alkane, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 3-6 Carbocyclic group, substituted or unsubstituted benzene ring.

[0015] Substituted amino groups include, but are not limited to, monosubstituted amino-NHR a and disubstituted amino-NR a R a Including but not limited to substituted or unsubstituted C 1-6 alkyl.

[0016] Halogen groups -X include, but are not limited to, -F, -Cl, -Br, and -I. Pseudohalogen groups include, but are not limited to, -CN and -N3.

[0017] The acyl group has the structural formula -OCO-R x R x Including but not limited to substituted or unsubstituted C 1-6 Alkyl-substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 3-6 Carbon cyclic group.

[0018] Substituted or unsubstituted phenyl refers to hydroxylated phenyl, methyl ether-substituted phenyl, diethyl ether-substituted phenyl, and nitro-substituted phenyl.

[0019] R7 includes, but is not limited to, hydrogen atoms, carboxyl groups, ester groups, amide groups, sulfonic acid groups, and ester groups.

[0020] R8 and R9 are hydrogen atoms, hydroxyl groups, or thiol groups, and at least one of them is a hydroxyl group.

[0021] In formula (I), the aromatic group Ar can be a benzene ring, naphthalene, pyrrole, furan, or thiophene. Any site on Ar can be substituted with an alkyl, nitro, cyano, trifluoromethyl, sulfonyl, acyl, ester, or halogen atom. Substituents in formula (I) that are attached to the aromatic group and have a dopamine-like structure and function can be attached to any carbon or heteroatom of the aromatic group.

[0022] In formula (Ⅰ), the brackets indicate the part containing the brackets and m or n, representing a straight-chain alkyl segment composed of m or n methylene (CH2) groups, i.e., -(CH2) at that structural position. m -or-(CH2) n -, m and n are integers representing the number of methylene groups, used to define the possible length of the carbon chain. m and n can be integers from 0 to 6.

[0023] Preferably, the structure of the BODIPY derivative is shown in general formula (I-A):

[0024]

[0025] R7 is a hydrogen atom.

[0026] R8 and R9 are hydroxyl groups.

[0027] Ar is a benzene ring and is para-substituted.

[0028] In formula (Ⅰ-A), R1, R2, R3, R4, R5, and R6 can be independently selected from hydrogen atoms, alkyl groups, alkenyl-, carbocyclic groups, alkoxy groups, amino or substituted amino groups, halogens, pseudohalogen groups, acyloxy groups, carbonyl groups, carboxyl-substituted or unsubstituted phenyl groups, and nitro groups. The aforementioned alkyl groups include, but are not limited to, substituted or unsubstituted C... 1-6 Alkyl and alkenyl groups, including substituted or unsubstituted C4 groups. 2-6 alkenyl;

[0029] Carbocyclic groups include, but are not limited to, substituted or unsubstituted C groups. 3-6 carbon cyclo group;

[0030] The above-OR w Among them, R w Including but not limited to hydrogen atoms, substituted or unsubstituted C atoms 1-6 Alkane, substituted or unsubstituted C2-6 Alkenyl, substituted or unsubstituted C 3-6 Carbocyclic group, substituted or unsubstituted benzene ring;

[0031] Substituted amino groups include, but are not limited to, monosubstituted amino-NHR a and disubstituted amino-NR a R a Including but not limited to substituted or unsubstituted C 1-6 alkyl.

[0032] Halogen groups -X include, but are not limited to, -F, -Cl, -Br, and -I. Pseudohalogen groups include, but are not limited to, -CN and -N3.

[0033] Acyloxy-OCO-R x R x Including but not limited to substituted or unsubstituted C 1-6 Alkyl-substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 3-6 Carbon cyclic group.

[0034] Substituted or unsubstituted phenyl refers to hydroxylated phenyl, methyl ether-substituted phenyl, diethyl ether-substituted phenyl, and nitro-substituted phenyl.

[0035] Formula (Ⅰ-A) may be selected from the following implementation schemes, including but not limited to the following:

[0036]

[0037]

[0038]

[0039]

[0040] As another preferred embodiment, the structure of the BODIPY derivative is shown in general formula (I-B):

[0041]

[0042] In formula (Ⅰ-B), R1 is a methyl group, R2 is an iodine atom, R3 is a methyl group, R4 is a methyl group, R5 is an iodine atom, and R6 is a methyl group.

[0043] R7 is a hydrogen atom.

[0044] R8 and R9 are hydroxyl groups.

[0045] m can be any integer between 0 and 5.

[0046] In formula (I), the Ar aromatic group in combination 2 can be a benzene ring, naphthalene, pyrrole, furan, or thiophene. Furthermore, any site on the phenyl group can be substituted with an alkyl, cyano, trifluoromethyl, sulfonyl, acyl, ester, or halogen atom. Substituents in formula (I) that are attached to the aromatic group and have a dopamine-like structure and function can be attached to any carbon or heteroatom of the aromatic group.

[0047]

[0048] Compound (Ⅰ-B) may be selected from the following embodiments, including but not limited to the following embodiments.

[0049]

[0050]

[0051]

[0052] As another preferred embodiment, the structure of the BODIPY derivative is shown in general formula (I-C):

[0053]

[0054] In formula (Ⅰ-C), R1 is a methyl group, R2 is an iodine atom, R3 is a methyl group, R4 is a methyl group, R5 is an iodine atom, and R6 is a methyl group.

[0055] R7 includes, but is not limited to, hydrogen atoms, carboxyl groups, ester groups, amide groups, sulfonic acid groups, and ester groups.

[0056] R8 and R9 are hydrogen atoms, hydroxyl groups, or thiols, and at least one of them is a hydroxyl group.

[0057] Ar is a benzene ring and is para-substituted;

[0058] n is an integer between 0 and 5.

[0059] Compound (Ⅰ-C) may be selected from the following specific compounds.

[0060]

[0061]

[0062] Compared with the prior art, the beneficial effects of the present invention are reflected in:

[0063] This invention discloses a novel biomimetic photodynamic antibacterial coating compound based on mussels. This compound not only imparts excellent substrate adhesion to the coating but also achieves highly efficient photodynamic antibacterial effects. Simultaneously, it effectively overcomes the shortcomings of existing technologies: the preparation process is relatively simple and cost-effective; film formation and use are not subject to strict pH limitations; and it can be stably fixed on the surfaces of common materials. Furthermore, this invention also provides a method for synthesizing this compound and its applications, offering a new solution to the problem of simultaneously achieving antibacterial and adhesive properties on material surfaces. Attached Figure Description

[0064] Figure 1 The elution buffer for test example 1 (blank) and materials 2 and 8, after 24 hours of light incubation, was diluted 10. 5 Coating results.

[0065] Figure 2 For compound 1 1 H NMR spectrum.

[0066] Figure 3 For compound 2 1 H NMR spectrum.

[0067] Figure 4 For compound 4 1 H NMR spectrum.

[0068] Figure 5 For compound 5 1 H NMR spectrum. Detailed Implementation

[0069] To enable those skilled in the art to better understand the technical means and creative features of this invention, the technical solutions in the embodiments of this invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are merely some, not all, of the embodiments of this invention. All other embodiments obtained by those skilled in the art based on the embodiments of this invention without creative effort should fall within the scope of protection of this invention.

[0070] It should be noted that the terms "comprising" and "having," and any variations thereof, are intended to cover non-exclusive inclusion, for example, a process, method, system, product, or device that includes a series of steps or units is not necessarily limited to those steps or units that are explicitly listed, but may include other steps or units that are not explicitly listed or that are inherent to such process, method, product, or device.

[0071] The present invention will be further described in detail below with reference to specific embodiments:

[0072] The following synthetic route describes the preparation of one of the compounds of general formula (I) of the present invention. All starting materials are prepared by the methods described in these chemical formulas, by methods well known to those skilled in the art of organic chemistry, or are commercially available. All final compounds of the present invention are prepared by the methods described in these chemical formulas or by similar methods well known to those skilled in the art of organic chemistry. All variable factors used in these chemical formulas are defined as follows or as defined above.

[0073] The following is the synthetic procedure for one of the compounds (Ⅰ-A1).

[0074] According to the general formula (I) compounds of the present invention, R1, R2, R3, R4, R5, R6, R7, R8, R9 and Ar, as defined in the foregoing content section, can all be prepared by the following method.

[0075]

[0076] Step 1: Weigh p-aldehyde benzoic acid (0.50 g, 3.33 mmol, 1 eq) into a dry reactor dish. Add 290 mL of anhydrous and oxygen-free dichloromethane to dissolve the p-aldehyde benzoic acid. While stirring, add 0.67 mL of 2,4-dimethylpyrrole (6.65 mmol, 2 eq) and trifluoroacetic acid (12.5 μL, 0.16 mmol, 0.05 eq) as a catalyst. React under nitrogen protection for 18 h.

[0077] Dichlorodicyanoquinone (0.75 g, 3.30 ml, 1 eq) was dissolved in ultra-dry tetrahydrofuran under nitrogen protection and added dropwise to the above reaction solution. The mixture was stirred at room temperature for 30 min. Triethylamine (6.5 ml, 46 mmol, 14 eq) and boron trifluoride diethyl ether complex (6.6 ml, 53.4 mmol, 16 eq) were added sequentially, and the reaction was continued for 24 h. The product was extracted with distilled water and dichloromethane, dried over anhydrous sodium sulfate, separated by column chromatography, and evaporated to dryness to give a purple-brown product 1.

[0078]

[0079] Step 2: A magnetic stir bar was placed in a 50 ml reaction flask containing the rotary-dried product (82.3 mg, 0.2236 mmol, 1 eq). 15 ml of anhydrous dichloromethane was added to the flask, taking care to rinse and dissolve the product on the flask wall to obtain solution ①. The iodosuccinimide (NIS) powder (201.1 mg, 0.8942 mmol, 4 eq) was weighed and completely dissolved in 2 ml of anhydrous methanol to obtain solution ②. Solution ② was slowly added dropwise to solution ① and reacted for 1 h. TLC was performed to confirm that the reaction was complete, and the product was a magenta main spot.

[0080] Wash with 20ml of saturated NaCl, evaporate the anhydrous sodium sulfate organic phase to dryness, add silica gel to prepare a dry sample, pack a silica gel column with dichloromethane using a wet method, and separate and purify with dichloromethane-methanol 10:1 (v / v). The elution solution is bright red to purplish red. After drying, a relatively pure iodinated product 2 is obtained.

[0081]

[0082] Step 3: Weigh and add dopamine hydrochloride (1.26 g, 6.61 mmol, 1 eq) and imidazole (1.795 g, 16.5 mmol, 2.5 eq) into a dry 100 ml reaction flask and a magnetic reaction flask. Finally, add weighed tert-butylchlorosilane (2.485 g, 26.35 mmol, 4 eq) under nitrogen protection, add 30 ml of anhydrous and oxygen-free dichloromethane, and react for 16 h to produce a milky white suspension.

[0083] Washing and purification: Filter the reaction solution to remove the suspended solids (also rinse down the bottle wall for filtration), rotary evaporate to obtain a viscous substance, pour into 50ml of ethyl acetate to dissolve, wash with 2*50ml of saturated sodium bicarbonate, 25ml of deionized water, and 25ml of saturated sodium chloride in turn, dry with anhydrous sodium sulfate, and rotary evaporate the resulting solution (as dry as possible) to obtain a viscous, pale yellow to slightly pink transparent viscous product 3.

[0084]

[0085] Step 4: Weigh product 3 (272.2 mg, 0.7140 mmol, 1.5 eq) and product 2 (295.1 mg, 0.4760 mmol, 1 eq) using a double-necked flask. Dissolve and transfer product 2 from the flask in step 2 to the double-necked reaction flask using 23 ml of anhydrous dichloromethane. Wash the flask walls with 2 ml of anhydrous dichloromethane and combine the products into the double-necked flask. Add a magnetic stir bar.

[0086] 1-Ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (1054.9 mg, 0.5474 mmol, 1.15 eq) was added to an ice-water bath, followed by 4-dimethylaminopyridine (20.4 mg, 0.1666 mmol, 0.35 eq) as a catalyst. The reaction was carried out for 1 h, then the ice-water bath was removed, and the mixture was refluxed for 24 h. TLC was performed using dichloromethane-methanol 10:1 (v / v).

[0087] To determine the completeness of the reaction, the ratio of dichloromethane to n-hexane 4:1 (v / v) is used to determine the purity of the reaction.

[0088] Washing and purification: The mixture was washed sequentially with 0.1M dilute hydrochloric acid solution, saturated sodium bicarbonate solution, and saturated sodium chloride solution. The organic phase was then collected and dried over anhydrous sodium sulfate. The solvent was removed using a rotary evaporator to obtain the crude product. The crude product was purified by silica gel column chromatography using dichloromethane-n-hexane 4:1 (v / v) to obtain a red, slightly viscous solid product 4.

[0089] Step 5:

[0090]

[0091] Product 4 (35.4 mg, 0.037 mmol, 1 eq) was collected and placed in a 25 ml reaction flask. Under nitrogen protection, 2 ml of anhydrous and oxygen-free tetrahydrofuran was injected to dissolve the product, and the mixture was pre-cooled in an ice-water bath.

[0092] Under nitrogen protection, 1M tetrabutylammonium fluoride was diluted tenfold with tetrahydrofuran in a 10ml double-necked flask. 0.89ml of this diluted tetrabutylammonium fluoride solution (calculated concentration: 80μL, 0.080 mmol / L, 2.2 eq) was slowly added dropwise over a period of at least five minutes to the product solution (Solution 4) in an ice-water bath. After the addition was complete, the reaction was allowed to proceed for 40 minutes in the ice-water bath. During this time, samples were taken and observed on a TLC plate. The TLC plate analysis used a dichloromethane-methanol ratio of 10:1 (v / v) to determine the completeness of the reaction, and a dichloromethane-n-hexane ratio of 4:1 (v / v) to determine the purity. Product solution (Solution 5) was red, and the reaction solution was purple-red.

[0093] The reaction was then quenched by adding 5 mL of 0.1 M sodium phosphate buffer (pH 7.0) and 5 mL of ethyl acetate. The organic layer was washed with 2 × 5 mL of sodium phosphate buffer and 2 × 5 mL of saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. A red solution was obtained. The concentrate was purified by silica gel plate separation using chloromethane-n-hexane 4:1 (v / v) as the developing solvent to give product 5, a red solid with a golden luster, namely compound (Ⅰ-A1).

[0094] Test Example 1: Preparation of Antibacterial Film

[0095] Taking compound (Ⅰ-A1) as an example, compound (Ⅰ-A1) was dissolved in anhydrous methanol at a concentration of 1 mg / ml. A cleaned glass slide was suspended from a beaker by a thin string, partially immersed in the compound (Ⅰ-A1)-methanol solution. The solution was stirred vigorously for 2 hours and 8 hours to polymerize the compound onto the glass slide; the polymer turned a deep purple. Methanol was then used for immersion and cleaning to remove loosely adhered material.

[0096] Antibacterial test

[0097] strains used

[0098] 1. Escherichia coli AS1.90

[0099] 2. Staphylococcus aureus AS1.89 equivalent to ATCC6538p material formulation

[0100] LB medium

[0101] Plate counting agar LB agar plates

[0102] Phosphate-buffered saline (PBS, 0.06 mol / L) eluent

[0103] Dissolve 2.7g potassium dihydrogen phosphate, 7.0g dipotassium hydrogen phosphate, and 8.5g sodium chloride in distilled water to 1000mL to facilitate bacterial elution (do not add a small amount of surfactant such as Tween-80). Autoclave at 121℃ for 15min. The sterilized eluent should be stored at 5℃~10℃ for no more than 30 days.

[0104] Detailed operating steps

[0105] 1. Preparation of inoculum

[0106] The solution used for preparing Escherichia coli suspension is a sterile aqueous dilution, and the solution used for preparing Staphylococcus aureus suspension is also a sterile aqueous dilution. Adjust the pH to 7.0–7.2 at room temperature using 0.1 mol / L sodium hydroxide or 0.1 mol / L hydrochloric acid solution. To facilitate bacterial dispersion, a small amount of neutral surfactant (such as 1% Tween-80, optional) can be added.

[0107] After overnight culture of E. coli, a 1% inoculum was transferred to fresh LB medium and cultured until the bacterial concentration reached 1 x 10⁻⁶. 8 CFU / mL, and select bacterial solutions with concentrations of (5-20)×10⁵ CFU / mL as test solutions by sequentially diluting them 10-fold. If the prepared inoculum is not used immediately, it should be stored at 4℃ and used within 4 hours.

[0108] 2. Sample preparation

[0109] After rinsing the sample with the photosensitive material (Ⅰ-A1) in sterile water, place it under a UV lamp for irradiation (do not wipe). For photocatalytic samples, clean the sample surface by irradiating it with a UV (UVC, main wavelength at 273.8nm) lamp at a power of not less than 1.0mW / cm2 for 4h to 24h; then let it stand for not less than 2h before starting the test.

[0110] 3. Vaccination

[0111] Place each sample from step 2 into a clean petri dish, test side facing upwards. Accurately measure 0.2 mL of the inoculum solution prepared in step 1 and add it dropwise to the surface of each sample (the purple part represents the fixation of different concentrations of photosensitive material, and the transparent part represents the absence of photosensitive material; the bacterial solution is added to the purple part), ensuring the bacterial solution is evenly dispersed. Care should be taken not to spill the bacterial solution, otherwise the test will be invalid. The control is a slide without fixation but with the same amount of bacterial solution added.

[0112] 4. Cultivation

[0113] Place in an incubator under light, at a temperature of 35℃±2℃ and a relative humidity of not less than 85%, for a period of 4h to 24h.

[0114] 5. Washing and counting

[0115] 5.1 Elution and counting of samples with "0" contact time

[0116] Add 20 mL of phosphate-buffered saline elution buffer to each of the three blank control samples with zero contact time. After thorough elution, proceed according to GB4789.2.

[0117] 5.2 Elution and counting of samples after incubation

[0118] (The cultured samples include glass slides containing antibacterial materials and glass slides containing blank control.) The samples were eluted using the same method as in step 5.1, and the viable bacteria count was performed on the eluent immediately afterwards.

[0119] If no colonies are found in any petri dish, record it as <1. If the bacterial count is not inversely proportional to the dilution ratio, consider whether the shedding of the antimicrobial agent is affecting colony formation.

[0120] 6. Calculation of viable bacteria count (Ask Xiao Luo).

[0121] The viable count N (CFU) is calculated according to formula (1):

[0122] N = C × D × V where:

[0123] C -- Colony count (average of 3 culture dishes) CFU;

[0124] D -- Dilution factor;

[0125] V -- The volume of eluent used for elution, in milliliters (mL).

[0126] The arithmetic mean of the viable bacterial counts of the three samples was taken, and the antibacterial experimental data were retained to two significant figures.

[0127] 1. Elution counts for "0" contact time

[0128]

[0129] 2. Elution count of samples after 24 hours of light incubation

[0130]

[0131]

Claims

1. A BODIPY derivative, characterized in that, A compound having a structure represented by the general formula (I): In the formula (I), R1, R2, R3, R4, R5 and R6 are independently selected from a hydrogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group, a C3-C8 carbocyclic group, a C1-C6 alkoxy group, an amino or substituted amino group, a halogen, a pseudohalogen group, a C1-C6 acyloxy group, a carbonyl group, a carboxyl group, an ester group, a substituted or unsubstituted phenyl group, a nitro group; R7 is a hydrogen atom or a carboxyl group, R8 and R9 are a hydroxyl group or a hydrogen atom; Ar is an aromatic group; m and n are integers from 0 to 6.

2. The BODIPY derivative according to claim 1, characterized in that, A compound having a structure represented by the general formula (I-A): R1, R2, R3, R4, R5 and R6 can be independently selected from a hydrogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group, a C3-C8 carbocyclic group, a C1-C6 alkoxy group, an amino or substituted amino group, a halogen, a pseudohalogen group, a C1-C6 acyloxy group, a carbonyl group, a carboxyl group, an ester group, a substituted or unsubstituted phenyl group, a nitro group.

3. The BODIPY derivative according to claim 2, wherein One of the following compounds:

4. The BODIPY derivative of claim 1, wherein A compound having a structure represented by the general formula (I-B): m is an integer from 0 to 5; Ar is an aromatic group, which is a phenylene group, a naphthylene group, a pyrrolylene group, a furanylene group or a thienylene group, and any position of the phenylene group can be substituted with a C1-C6 alkyl group, a cyano group, a trifluoromethyl group, a sulfonyl group, an acyl group, an ester group or a halogen atom.

5. The BODIPY derivative of claim 1, wherein One of the following compounds:

6. The BODIPY derivative of claim 1, wherein A compound represented by the general formula (I-C): R7 is a hydrogen atom, a carboxyl group, an ester group, an amide group, a sulfonic acid group or an ester group; R8 is independently selected from a hydrogen atom, a hydroxyl group or a mercapto group, and at least one of R8 is a hydroxyl group.

7. The BODIPY derivative of claim 1, wherein One of the following compounds:

8. Use of the BODIPY derivative according to any one of claims 1 to 7 in the field of preparing antibacterial materials.

9. Use according to claim 8, characterized in that, The BODIPY derivative is used for preparing an antibacterial coating on the surface of a material.

10. Use according to claim 8, characterized in that, The BODIPY derivative is used for inhibiting Escherichia coli or Staphylococcus aureus.

Images